These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 12518253

  • 1. Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers.
    von Mach MA, Brinkmann C, Hansen T, Weilemann LS, Beyer J.
    Exp Clin Endocrinol Diabetes; 2002 Nov; 110(8):416-9. PubMed ID: 12518253
    [Abstract] [Full Text] [Related]

  • 2. Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin.
    Heinemann L, Heise T, Wahl LC, Trautmann ME, Ampudia J, Starke AA, Berger M.
    Diabet Med; 1996 Jul; 13(7):625-9. PubMed ID: 8840095
    [Abstract] [Full Text] [Related]

  • 3. A comparison of preprandial insulin glulisine versus insulin lispro in people with Type 2 diabetes over a 12-h period.
    Luzio S, Peter R, Dunseath GJ, Mustafa L, Owens DR.
    Diabetes Res Clin Pract; 2008 Feb; 79(2):269-75. PubMed ID: 18164094
    [Abstract] [Full Text] [Related]

  • 4. Intramuscular versus subcutaneous injection of soluble and lispro insulin: comparison of metabolic effects in healthy subjects.
    Rave K, Heise T, Weyer C, Herrnberger J, Bender R, Hirschberger S, Heinemann L.
    Diabet Med; 1998 Sep; 15(9):747-51. PubMed ID: 9737803
    [Abstract] [Full Text] [Related]

  • 5. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.
    Raz I, Weiss R, Yegorchikov Y, Bitton G, Nagar R, Pesach B.
    Clin Ther; 2009 May; 31(5):980-7. PubMed ID: 19539098
    [Abstract] [Full Text] [Related]

  • 6. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects.
    Becker RH, Frick AD, Burger F, Potgieter JH, Scholtz H.
    Exp Clin Endocrinol Diabetes; 2005 Sep; 113(8):435-43. PubMed ID: 16151977
    [Abstract] [Full Text] [Related]

  • 7. A comparison of pharmacokinetics and pharmacodynamics of biphasic insulin aspart 30, 50, 70 and pure insulin aspart: a randomized, quadruple crossover study.
    Thorisdottir RL, Parkner T, Chen JW, Ejskjaer N, Christiansen JS.
    Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):216-21. PubMed ID: 19175369
    [Abstract] [Full Text] [Related]

  • 8. Insulin aspart improves meal time glycaemic control in patients with Type 2 diabetes: a randomized, stratified, double-blind and cross-over trial.
    Perriello G, Pampanelli S, Porcellati F, Avogaro A, Bosi E, Petrella G, Squatrito S, Furneri S, Marra G, Vitali L, Previti M, Cucinotta D.
    Diabet Med; 2005 May; 22(5):606-11. PubMed ID: 15842516
    [Abstract] [Full Text] [Related]

  • 9. A single-center, randomized, double-blind, three-way crossover study examining postchallenge glucose responses to human insulin 70/30 and insulin lispro fixed mixtures 75/25 and 50/50 in patients with type 2 diabetes mellitus.
    Schwartz S, Zagar AJ, Althouse SK, Pinaire JA, Holcombe JH.
    Clin Ther; 2006 Oct; 28(10):1649-57. PubMed ID: 17157120
    [Abstract] [Full Text] [Related]

  • 10. Efficacy comparison between preprandial and postprandial insulin aspart administration with dose adjustment for unpredictable meal size.
    Jovanovic L, Giammattei J, Acquistapace M, Bornstein K, Sommermann E, Pettitt DJ.
    Clin Ther; 2004 Sep; 26(9):1492-7. PubMed ID: 15531011
    [Abstract] [Full Text] [Related]

  • 11. A 2-way cross-over, open-labeled trial to compare efficacy and safety of insulin Aspart and Novolin R delivered with CSII in 21 Chinese diabetic patients.
    Bi YF, Zhao LB, Li XY, Wang WQ, Sun SY, Chen YH, Hong J, Su TW, Liu JM, Ning G.
    Chin Med J (Engl); 2007 Oct 05; 120(19):1700-3. PubMed ID: 17935674
    [Abstract] [Full Text] [Related]

  • 12. The addition of acarbose to insulin lispro reduces acute glycaemic responses in patients with type-2 diabetes.
    Hermanns N, Burkert A, Haak T.
    Exp Clin Endocrinol Diabetes; 2004 Jun 05; 112(6):310-4. PubMed ID: 15216448
    [Abstract] [Full Text] [Related]

  • 13. Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart.
    Ashwell SG, Gebbie J, Home PD.
    Diabet Med; 2006 Aug 05; 23(8):879-86. PubMed ID: 16911626
    [Abstract] [Full Text] [Related]

  • 14. Counterregulatory hormone responses and symptoms during hypoglycaemia induced by porcine, human regular insulin, and Lys(B28), Pro(B29) human insulin analogue (insulin Lispro) in healthy male volunteers.
    Jacobs MA, Salobir B, Popp-Snijders C, Ader H, Heine RJ.
    Diabet Med; 1997 Mar 05; 14(3):248-57. PubMed ID: 9088775
    [Abstract] [Full Text] [Related]

  • 15. Use of a novel double-antibody technique to describe the pharmacokinetics of rapid-acting insulin analogs.
    Lindström T, Hedman CA, Arnqvist HJ.
    Diabetes Care; 2002 Jun 05; 25(6):1049-54. PubMed ID: 12032113
    [Abstract] [Full Text] [Related]

  • 16. Comparison of the time-action profiles of U40- and U100-regular human insulin and the rapid-acting insulin analogue B28 Asp.
    Heinemann L, Weyer C, Rave K, Stiefelhagen O, Rauhaus M, Heise T.
    Exp Clin Endocrinol Diabetes; 1997 Jun 05; 105(3):140-4. PubMed ID: 9228509
    [Abstract] [Full Text] [Related]

  • 17. The effect of improved post-prandial blood glucose control on post-prandial metabolism and markers of vascular risk in people with Type 2 diabetes.
    Gallagher A, Home PD.
    Diabetes Res Clin Pract; 2005 Mar 05; 67(3):196-203. PubMed ID: 15713351
    [Abstract] [Full Text] [Related]

  • 18. Differential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide, at the same glycemic control.
    Chisalita SI, Lindström T, Eson Jennersjö P, Paulsson JF, Westermark GT, Olsson AG, Arnqvist HJ.
    Acta Diabetol; 2009 Mar 05; 46(1):35-42. PubMed ID: 18777156
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes.
    Hompesch M, Ocheltree SM, Wondmagegnehu ET, Morrow LA, Kollmeier AP, Campaigne BN, Jacober SJ.
    Curr Med Res Opin; 2009 Nov 05; 25(11):2679-87. PubMed ID: 19761358
    [Abstract] [Full Text] [Related]

  • 20. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers.
    Home PD, Barriocanal L, Lindholm A.
    Eur J Clin Pharmacol; 1999 May 05; 55(3):199-203. PubMed ID: 10379635
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.